Payment overview · 2025
General Payments
$1,292.26
57 reported records · 5 companies
Healthcare provider profile · identity verified
Gissy L Suarez
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TAMPA, FL · NPI 1013687771
Verified facts
What the public records show
CMS Open Payments records show Gissy L Suarez received $1,292.26 in general payments during 2025 across 57 reported records.
Gilead Sciences, Inc. accounted for 52.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Biktarvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $680.89 | 52.7% | 32 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $391.81 | 30.3% | 15 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $186.33 | 14.4% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.41 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.82 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,292.26 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $161.10 | 7 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $140.92 | 7 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $128.09 | 6 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $119.50 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $91.27 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $48.51 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 98 |
| Lisinopril | Lisinopril | 263 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 101 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 94 |
| Losartan Potassium | Losartan Potassium | 201 | 67 |
| Omeprazole | Omeprazole | 179 | 79 |
| Gabapentin | Gabapentin | 175 | 83 |
| Metformin Hcl | Metformin Hcl | 161 | 57 |
| Trazodone Hcl | Trazodone Hcl | 140 | 61 |
| Methylprednisolone | Methylprednisolone | 134 | 98 |
| Furosemide | Furosemide | 126 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 79 |
| Alendronate Sodium | Alendronate Sodium | 91 | 37 |
| Azithromycin | Azithromycin | 91 | 73 |
| Simvastatin | Simvastatin | 90 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 83 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 40 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Ibuprofen | Ibuprofen | 77 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 48 |
| Montelukast Sodium | Montelukast Sodium | 74 | 31 |
| Tramadol Hcl | Tramadol Hcl | 74 | 27 |
| Memantine Hcl | Memantine Hcl | 71 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 21 |
| Famotidine | Famotidine | 63 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 37 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 47 |
| Ozempic | Semaglutide | 57 | 15 |
| Carvedilol | Carvedilol | 54 | 28 |
| Alprazolam | Alprazolam | 50 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 21 |
| Glipizide | Glipizide | 50 | 25 |
| Spironolactone | Spironolactone | 50 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 19 |
| Metformin Hcl Er | Metformin Hcl | 44 | 17 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 28 |
| Amoxicillin | Amoxicillin | 40 | 35 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 40 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 35 |
| Atenolol | Atenolol | 38 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 21 |
| Baclofen | Baclofen | 34 | 19 |
| Eliquis | Apixaban | 34 | 15 |
| Meloxicam | Meloxicam | 34 | 13 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 14 |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Finasteride | Finasteride | 26 | 11 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 13 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Potassium Chloride | Potassium Chloride | 23 | 12 |
| Topiramate | Topiramate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 13 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Allopurinol | Allopurinol | 19 | 12 |
| Nystatin | Nystatin | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Prednisone | Prednisone | 17 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,292.26 · 57 records | Gilead Sciences, Inc. | ABRYSVO, APRETUDE, Biktarvy, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DOVATO, GARDASIL 9, PIFELTRO, PREVNAR 20, Yeztugo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error